Gerald Commissiong - Todos Medical Pres CEO
Insider
Gerald Commissiong is Pres CEO of Todos Medical
| Age | 40 |
| Phone | 972 52 642 0126 |
| Web | https://todosmedical.com |
Todos Medical Management Efficiency
The company has return on total asset (ROA) of (0.4591) % which means that it has lost $0.4591 on every $100 spent on assets. This is way below average. Todos Medical's management efficiency ratios could be used to measure how well Todos Medical manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Kristin Gibbs | Sotera Health Co | N/A | |
| Mike McAlduff | Sona Nanotech | N/A | |
| Lehmann JD | Sotera Health Co | 56 | |
| Matthew Molchan | Star Equity Holdings | 57 | |
| Claire Sears | Neuronetics | N/A | |
| Keith Meadors | Precipio | N/A | |
| Heinrich Rder | Biodesix | N/A | |
| Richard Coleman | Star Equity Holdings | 68 | |
| Matthew Gage | Precipio | 57 | |
| Ranjan Jayanathan | RadNet Inc | 68 | |
| Ahmed Sabet | Precipio | 38 | |
| Ryan Siurek | Biodesix | 52 | |
| Thomas Theuringer | Qiagen NV | N/A | |
| Michael Petras | Sotera Health Co | 55 | |
| Darren Rowles | Sona Nanotech | 43 | |
| Paul Beresford | Biodesix | N/A | |
| Miri ChikoRadomski | Precipio | N/A | |
| David Noble | Star Equity Holdings | 54 | |
| David Regan | Sona Nanotech | N/A | |
| Kulbir Singh | Sona Nanotech | N/A | |
| Jeffrey Bojar | Biodesix | N/A | |
Management Performance
| Return On Asset | -0.46 |
Todos Medical Leadership Team
Elected by the shareholders, the Todos Medical's board of directors comprises two types of representatives: Todos Medical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Todos. The board's role is to monitor Todos Medical's management team and ensure that shareholders' interests are well served. Todos Medical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Todos Medical's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Chris Gross, VP Operations | ||
| Paula MD, Chief Neurology | ||
| Ilanit CPA, Co Controller | ||
| Jorge Leon, Chief Officer | ||
| Daniel Hirsch, CFO Director | ||
| Joseph Wee, Managing Singapore | ||
| Gerald Commissiong, Pres CEO |
Todos Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Todos Medical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Asset | -0.46 | |||
| Operating Margin | (1.07) % | |||
| Current Valuation | 49.61 M | |||
| Shares Outstanding | 1.41 B | |||
| Shares Owned By Insiders | 11.17 % | |||
| Shares Owned By Institutions | 4.81 % | |||
| Price To Earning | (90.00) X | |||
| Price To Sales | 1.30 X | |||
| Revenue | 12.23 M | |||
| Gross Profit | 4.38 M |
Currently Active Assets on Macroaxis
Other Information on Investing in Todos Pink Sheet
Todos Medical financial ratios help investors to determine whether Todos Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Todos with respect to the benefits of owning Todos Medical security.